Vaxart Rises on Optimism of Potential Oral COVID Variant Pil

Vaxart Rises on Optimism of Potential Oral COVID Variant Pill


Original:
Vaxart  (
VXRT) - Get Report shares fell Monday, reversing gains in premarket trading, ahead of a presentation from the company’s founder and chief scientific officer that is expected to reveal its Phase 1 clinical trials of an oral vaccine that shows promise in protecting against COVID variants.
Shares of Vaxart were up 12.62% at $12.14 in premarket trading ahead of the presentation from its founder and chief scientific officer, Dr. Sean Tucker, on the importance of T-cell immunity in COVID-19 vaccines. 
At the open, the stock fell 7.51% to $9.97. The oral vaccine development firm’s name has popped up frequently in social media chat rooms. 

Related Keywords

Washington , United States , Sean Tucker , Andrei Floroiu , World Vaccine Congress Washington , Investing , Stocks , Lifestyle , Latest News , Biotechnology , Pharmaceuticals , Health , Drug Approvals , வாஷிங்டன் , ஒன்றுபட்டது மாநிலங்களில் , சீன் டக்கர் , உலகம் தடுப்பூசி காங்கிரஸ் வாஷிங்டன் , முதலீடு , ஸ்டாக்ஸ் , வாழ்க்கை , சமீபத்தியது செய்தி , உயிரி தொழில்நுட்பவியல் , மருந்துகள் , ஆரோக்கியம் ,

© 2025 Vimarsana